These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 33789452)

  • 1. The Future of Ketamine in the Treatment of Teen Depression.
    Parikh T; Walkup JT
    Am J Psychiatry; 2021 Apr; 178(4):288-289. PubMed ID: 33789452
    [No Abstract]   [Full Text] [Related]  

  • 2. Esketamine as a treatment for paediatric depression: questions of safety and efficacy.
    Zimmermann KS; Richardson R; Baker KD
    Lancet Psychiatry; 2020 Oct; 7(10):827-829. PubMed ID: 31952957
    [No Abstract]   [Full Text] [Related]  

  • 3. Esketamine (Spravato) for Treatment-Resistant Depression.
    Jalloh M
    Am Fam Physician; 2020 Mar; 101(6):339-340. PubMed ID: 32163257
    [No Abstract]   [Full Text] [Related]  

  • 4. Esketamine for treatment resistant depression: a trick of smoke and mirrors?
    Gastaldon C; Papola D; Ostuzzi G; Barbui C
    Epidemiol Psychiatr Sci; 2019 Dec; 29():e79. PubMed ID: 31841104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Esketamine for treatment resistant depression.
    Swainson J; Thomas RK; Archer S; Chrenek C; MacKay MA; Baker G; Dursun S; Klassen LJ; Chokka P; Demas ML
    Expert Rev Neurother; 2019 Oct; 19(10):899-911. PubMed ID: 31282772
    [No Abstract]   [Full Text] [Related]  

  • 6. Esketamine for resistant depression in older people with cognitive impairment: A case report.
    Romani S; Jacquet B; Cohen D; Curiale V; Laurent I; Louchart De La Chapelle S
    Encephale; 2023 Dec; 49(6):651-653. PubMed ID: 37604711
    [No Abstract]   [Full Text] [Related]  

  • 7. Ketamine and Esketamine for Treatment-Resistant Depression: Response to Reus, Mattes, and Schatzberg.
    McIntyre RS
    Am J Psychiatry; 2021 Dec; 178(12):1130-1132. PubMed ID: 34855455
    [No Abstract]   [Full Text] [Related]  

  • 8. Is Intravenous Ketamine Better Than Intranasal Esketamine for Treating Treatment-Resistant Depression?
    Mansuri Z; Shah B; Yadav G; Kamil SH; Kainth T; Srinivas S; Patel H; Reddy A; Bachu A
    Prim Care Companion CNS Disord; 2024 Feb; 26(1):. PubMed ID: 38382071
    [No Abstract]   [Full Text] [Related]  

  • 9. Promises and concerns regarding the use of ketamine and esketamine in the treatment of depression.
    Pérez-Esparza R; Kobayashi-Romero LF; García-Mendoza AM; Lamas-Aguilar RM; Fonseca-Perezamador A
    Acta Psychiatr Scand; 2019 Aug; 140(2):182-183. PubMed ID: 31251388
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
    Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB
    Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
    Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
    Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the Trajectory of Depression Severity With Ketamine and Esketamine Treatment in a Clinical Setting.
    Nikayin S; Rhee TG; Cunningham ME; de Fontnouvelle CA; Ostroff RB; Sanacora G; Wilkinson ST
    JAMA Psychiatry; 2022 Jul; 79(7):736-738. PubMed ID: 35544190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
    Murrough JW; Burdick KE; Levitch CF; Perez AM; Brallier JW; Chang LC; Foulkes A; Charney DS; Mathew SJ; Iosifescu DV
    Neuropsychopharmacology; 2015 Mar; 40(5):1084-90. PubMed ID: 25374095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to commentary on the comparative efficacy of esketamine vs. ketamine meta-analysis: Putting the cart before the horse?
    Bahji A; Vazquez GH; Zarate CA
    J Affect Disord; 2021 Mar; 282():258-260. PubMed ID: 33418376
    [No Abstract]   [Full Text] [Related]  

  • 15. Comments to Drs. Bahji, Vazquez, and Zarate.
    Drevets WC; Popova V; Daly EJ; Borentain S; Lane R; Cepeda MS; Mathews M; Manji HK; Canuso CM
    J Affect Disord; 2021 Mar; 283():262-264. PubMed ID: 33571795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Esketamine/ketamine for treatment-resistant depression.
    Lacerda ALT
    Braz J Psychiatry; 2020; 42(6):579-580. PubMed ID: 32401866
    [No Abstract]   [Full Text] [Related]  

  • 17. Are ketamine and its enantiomers the answer to treatment-refractory depression?
    Belge JB; Scantamburlo G; Constant E
    Expert Rev Neurother; 2024 Sep; 24(9):827-830. PubMed ID: 38932620
    [No Abstract]   [Full Text] [Related]  

  • 18. Esketamine Nasal Spray for Treatment-Resistant Depression.
    Fantasia HC
    Nurs Womens Health; 2020 Jun; 24(3):228-232. PubMed ID: 32387141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. US Food and Drug Administration approval of esketamine and brexanolone.
    Cristea IA; Naudet F
    Lancet Psychiatry; 2019 Dec; 6(12):975-977. PubMed ID: 31680013
    [No Abstract]   [Full Text] [Related]  

  • 20. Intranasal esketamine for depression: Not so special K.
    Rosenman S
    Australas Psychiatry; 2022 Aug; 30(4):533-534. PubMed ID: 35491953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.